Humanwell medicine class 3.1 antiemetic, fosapritam, dimethylmeglumine, has been accepted for clinical application
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the website of the State Food and Drug Administration (CFDA) on June 4, Yichang humanwell, a subsidiary of humanwell pharmaceutical Holding Co., Ltd., applied for the clinical application of fosapitam, a class 3.1 chemical drug, and fosapitam, a raw material drug and a preparation for injection, were accepted At present, there is no domestic enterprise to produce the product, and the original research drug has not entered the market of our country Fosapitam for injection is mainly used for the prevention and treatment of acute and delayed nausea and vomiting caused by chemotherapy It was first developed by Merck company and was listed in the United States in January 2008 It has entered Sweden, Czech Republic, Portugal, the United Kingdom and other countries, but has not yet entered China According to the public data, the purchase amount of antiemetics in sample hospitals has been increasing year by year In 2011, the drug purchase amount of sample hospitals exceeded 800 million yuan, and the total market size of the whole country is estimated to be 1.5-2 billion yuan Experts predict that palonosetron, aripitan and fosapitam are the three major antiemetics in the future CFDA shows that, at present, the original research drug of fosapitam for injection has not yet applied for registration in China Apart from Yichang humanwell, only Shandong Luoxin Pharmaceutical Co., Ltd has applied for the product
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
